These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37119243)

  • 1. The correlation of EMT and p53 immunohistochemical markers with cisplatin resistance in muscle invasive bladder cancer patients: A single-centred study.
    Paramanantham Y; B M Said NA; Mun KS
    Malays J Pathol; 2023 Apr; 45(1):19-29. PubMed ID: 37119243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Singh R; Singh UP; Agrawal V; Garg M
    Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
    Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.
    Tripathi K; Maurya N; Goel A; Singhai A; Garg M
    Mol Cell Biochem; 2023 Jun; 478(6):1169-1190. PubMed ID: 36239855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement.
    Brambs CE; Horn LC; Mende M; Höckel M; Eckey C; Hiller GGR; Höhn AK
    J Cancer Res Clin Oncol; 2022 May; 148(5):1183-1193. PubMed ID: 34495397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of epithelial-mesenchymal transition phenotypes in upper urinary tract urothelial carcinoma.
    Cho J; Ha SY; Kim SH; Sung HH; Kwon GY
    Pathol Res Pract; 2018 Apr; 214(4):547-554. PubMed ID: 29572121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
    Zhao J; Dong D; Sun L; Zhang G; Sun L
    Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin and N-cadherin Immunohistochemical Expression in Proliferating Urothelial Lesions: Potential Novel Cancer Predictive EMT Profiles.
    Shash LS; Ibrahim RA; Elgohary SA
    Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):657-666. PubMed ID: 33979097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p63 expression defines a lethal subset of muscle-invasive bladder cancers.
    Choi W; Shah JB; Tran M; Svatek R; Marquis L; Lee IL; Yu D; Adam L; Wen S; Shen Y; Dinney C; McConkey DJ; Siefker-Radtke A
    PLoS One; 2012; 7(1):e30206. PubMed ID: 22253920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer.
    Zhu Z; Zhu Z; Pang Z; Xing Y; Wan F; Lan D; Wang H
    Int J Oncol; 2013 Apr; 42(4):1271-8. PubMed ID: 23403865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin.
    Xiao S; Liu L; Lu X; Long J; Zhou X; Fang M
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1465-74. PubMed ID: 25716692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
    Li Y; Yang X; Su LJ; Flaig TW
    Oncol Rep; 2010 Oct; 24(4):1019-28. PubMed ID: 20811684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of epithelial-mesenchymal transition-related markers between cancer tissue and tumor emboli].
    He N; Wu GF; Zhao HY; Han HX
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):758-61. PubMed ID: 22336160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.
    Singh R; Mandhani A; Agrawal V; Garg M
    Cancer Microenviron; 2018 Jun; 11(1):23-39. PubMed ID: 29349669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.